RHEUMATOID FACTOR IN GENERAL MEDICAL PRACTICE: PART I - SPECIAL FEATURES OF LABORATORY DIAGNOSTICS, DETECTABILITY AND CLINICAL SIGNIFICANCE IN RHEUMATIC DISEASES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review presents data on the significance of rheumatoid factor (RF) in various rheumatic diseases. It has been shown that the determination of the IgM-RF level is used in clinical practice for the diagnosis of rheumatoid arthritis. At the same time, IgM-RF is a sensitive, but not sufficiently specific indicator found in serum and in other rheumatic diseases.

Full Text

Restricted Access

About the authors

Vera V. LYALINA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: vera_lyalina@mail.ru
PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Elina A. SKRIPNICHENKO

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: elkaskrip@gmail.com
postgraduate student of the Department of hospital therapy named after academician G.I. Storozhakov Moscow

Rostislav V. BINYAKOVSKY

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: binyakovskiy@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov Moscow

Svetlana V. BORISOVSKAYA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: svabor@inbox.ru
PhD., associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Victoria S. DOLGOPOLOVA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: dolgopolovavika@rambler.ru
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Tamara T. DEMURIA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: tamunademuria078@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Diana V. BABAYAN

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: dbabayan38@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Anna A. BOCHAROVA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: bocharova.aan@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Yulia V. POLYAKOVA

V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: kirichenkoyly@yandex.ru
therapist of the admission Department Moscow

Vadim A. GULSHIN

V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: vadimgulshin@gmail.com
therapist of the admission Department Moscow

Anna V. MODESTOVA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: a.modestowa@yandex.ru
PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Igor G. NIKITIN

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; National Medical Research Center «Treatment and Rehabilitation Center» of the Ministry of Healthcare of Russia

Email: igor.nikitin.64@mail.ru
MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Director of the National Medical Research Center «Treatment and rehabilitation center» of the Ministry of Healthcare of Russia Moscow

References

  1. Хоббс К. Лабораторные исследования. В книге: Акутота В., Арройо Р.А., Баттафарано Д.Ф. с соавт. Секреты ревматологии. Под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; с. 64-73. ISBN: 978-5-9704-4508-2.
  2. Gualtierotti R., Ciavarella T., Meroni P.L. Rheumatoid factors. In book: Autoantibodies. 3rd edition. Ed. by Shoenfeld Y., Meroni P.L., Gershwin V.E. Amsterdam: Elsevier B.V. 2014; 751-60. ISBN: 978-0-444-56378-1. https://dx.doi.org/10.1016/C2010-0-68545-2.
  3. Ryu H.J., Takeuchi F., Kuwata S. et al. The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis. Rheumatol Int. 2011; 3(31): 315-19. https://dx.doi.org/10.1007/s00296-009-1260-5.
  4. de Angelis V., Meroni P.L. Rheumatoid factors. In book: Autoantibodies. 1st edition. Ed. by Peters J.B., Schoenfeld Y. Amsterdam: Elsevier Inc. 2007; pp. 755-62. ISBN: 978-0-444-52763-9.
  5. Александрова Е.Н., Новиков А.А., Насонов Е.Л. Рекомендации по лабораторной диагностике ревматических заболеваний Общероссийской общественной организации «Ассоциация ревматологов России» - 2015. Современная ревматология. 2015; 4: 25-36. https://dx.doi.org/10.14412/1996-7012-2015-4-25-36.
  6. Jones J.G. Biochemistry of articular disorders. In book: Marshall W., Lapsley M., Day A., Ayling R. Clinical biochemistry: Metabolic and clinical aspects. 3rd edition. London: Churchill Livingstone. 2014; pp. 636-45. ISBN: 978-0-702-05140-1.
  7. Кишкун А.А. Клиническая лабораторная диагностика. М.: ГЭОТАР-Мелиа. 2010; с. 721-723. ISBN: 978-5-9704-1550-4.
  8. Фридрихсберг Д.А. Курс коллоидной химии. Спб.: Химия. Ленинградское отделение. 1995; с. 41. ISBN: 5-7245-1022-7.
  9. Жаворонок С.В., Тапальский Д.В. Иммуноферментный анализ. Учебное пособие. Гомель: Гомельский государственный медицинский университет. 2004; с. 6.
  10. Ameratunga R., Musaad S., Sugrue C., Kyle C. Rheumatoid factor measurement-continuing problems 70 years after discovery. Clin Rheumatol. 2011; 9(30): 1215-20. https://dx.doi.org/10.1007/s10067-011-1716-3.
  11. Devi C., Ravichandran R., Selvaraj L. et al.Comparative study of rheumatoid factor - IgM autoantibody testing by latex agglutination nephelometry and ELISA in patients with rheumatoid arthritis. Eur J Mol Clin Med. 2020. 8(7): 4521-27.
  12. Rocha K.C., Da Fonseca Brinque L.A., Oliveira C.G.B. et al.Comparative study between immunoturbidimetric and latex agglutination methods for the detection of rheumatoid factor. J Bras Patol Med Lab. 2013; 1(49): 12-16. https://dx.doi.org/10.1590/S1676-24442013000100002.
  13. Bas S., Perneger T.V., Kunzle E., Vischer T.L.Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis. 2002; 6(61): 505-10. https://dx.doi.org/10.1136/ard.61.6.505.
  14. Van Hoovels L., Jacobs J., Vander Cruyssen B. et al. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. Ann Rheum Dis. 2018; 5(77): 667-77. https://dx.doi.org/10.1136/annrheumdis-2017-212365.
  15. Клинические рекомендации. Ревматоидный артрит. Ассоциация ревматологов России. 2018. Рубрикатор Минздрава России. Доступ: https://cr.minzdrav.gov.ru/schema/250_1 (дата обращения - 16.08.2021).
  16. Shmerling R.H. Rheumatoid factor: Biology and utility of measurement. 2021. URL: https://www.uptodate.com/contents/rheumatoid-factor-biology-and-utility-of-measurement (date of access - 11.02.2022).
  17. Westwood O.M.R., Nelson P.N., Hay F.C. Rheumatoid factors: What's new? Rheumatology (Oxford). 2006; 45(4): 379-85. https://dx.doi.org/10.1093/rheumatology/kei228.
  18. Salzman B.E., Nevin J.E., Newman J.H. A primary care approach to the use and interpretation of common rheumatologic tests. Clin Fam Pract. 2005; 2(7): 335-58. https://dx.doi.org/10.1016/J.CFP.2005.02.009.
  19. Taylor P., Gartemann J., Hsieh J., Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis. 2011; 1(1): 1-18. https://dx.doi.org/10.4061/2011/815038.
  20. Лапин С.В., Мазинг А.В., Булгакова Т.В. с соавт. Клинические рекомендации по лабораторной диагностике аутоиммунных заболеваний. 2014. Доступ: https://medqualitypeople.ru/f/klinicheskie_rekomendacii_po_laboratornoj_diagnostike_autoimmunnyh_zabolevanij_0.pdf (дата обращения - 16.07.2021). URL: https://medqualitypeople.ru/f/klinicheskie_rekomendacii_po_laboratornoj_diagnostike_autoimmunnyh_zabolevanij_0.pdf (date of access - 16.07.2021) (In Russ.)].
  21. Bobbio-Pallavicini F., Alpini C., Caporali R. et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004; 6(3): R264-72. https://dx.doi.org/10.1186/ar1173.
  22. De Rycke L., Verhelst X., Kruithof E. et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005; 2(64): 299-302. https://dx.doi.org/10.1136/ard.2004.023523.
  23. Caramaschi P., Biasi D., Tonolli E. et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int. 2005; 1(26): 58-62. https://dx.doi.org/10.1007/s00296-004-0571-9.
  24. Chen H.A., Lin K.C., Chen C.H. et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 1(65): 35-39. https://dx.doi.org/10.1136/ard.2005.038851.
  25. Atzeni F., Sarzi-Puttini P., Dell' Acqua D. et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study. Arthritis Res Ther. 2005; 1(8): R3 https://dx.doi.org/10.1186/ar1851.
  26. Cambridge G., Leandro M.J., Edwards J.C.W. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003; 48(8): 2146-54. https://dx.doi.org/10.1002/art.11181.
  27. Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 9(54): 2793-806. https://dx.doi.org/10.1002/art.22025.
  28. Maneiro R.J., Salgado E., Carmona L., Gomez-Reino J.J. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2013; 1(43): 9-17. https://dx.doi.org/10.1016/j.semarthrit.2012.11.007.
  29. Faillace C., De Carvalho J.F. Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis. Rheumatol Int. 2013; 7(33): 1909-10. https://dx.doi.org/10.1007/s00296-012-2409-1.
  30. Deane K.D., O'Donnell C.I., Hueber W. et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010; 11(62): 3161-72. https://dx.doi.org/10.1002/art.27638.
  31. Deane K.D., Norris J.M., Holers V.M. Preclinical rheumatoid arthritis: Identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010; 2(36): 213-41. https://dx.doi.org/10.1016/j.rdc.2010.02.001.
  32. Федеральные клинические рекомендации по диагностике и лечению системной красной волчанки. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2018/07/18/clinrec_skv.pdf (дата обращения - 11.02.2022).
  33. Popescu C., Zofota S., Bojinca V., Ionescu R. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus. Rom J Intern Med. 2013; 51(3-4): 179-87.
  34. Fedrigo A., dos Santos T.A.F.G., Nisihara R., Skare T. The lupus patient with positive rheumatoid factor. Lupus. 2018; 27(8): 1368-73. https://dx.doi.org/10.1177/0961203318759607.
  35. Witte T., Hartung K., Sachse C. et al. Rheumatoid factors in systemic lupus erythematosus: Association with clinical and laboratory parameters. Rheumatol Int. 2000; 3(19): 107-11. https://dx.doi.org/10.1007/s002960050112.
  36. Федеральные клинические рекомендации по диагностике и лечению болезни Шегрена. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2018/07/18/clinrec_b_shyogrena.pdf (дата обращения - 11.02.2022).
  37. Bournia V.K., Vlachoyiannopoulos P.G. Subgroups of Sjogren syndrome patients according to serological profiles J Autoimmun. 2012; 39(1-2): 15-26. https://dx.doi.org/10.1016/j.jaut.2012.03.001.
  38. Wielosz E., Majdan M., Dryglewska M., Zwolak R. Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations. Adv Clin Exp Med. 2018; 27(9): 1253-57. https://dx.doi.org/10.17219/acem/69921.
  39. Ramos-Casals M., Solans R., Rosas J. et al. Primary Sjogren syndrome in Spain: Clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008; 87(4): 210-19. https://dx.doi.org/10.1097/MD.0b013e318181e6af.
  40. Martel C., Gondran G., Launay D. et al. Active immunological profile is associated with systemic Sjogren's syndrome. J Clin Immunol. 2011; 31(5): 840-47. https://dx.doi.org/10.1007/s10875-011-9553-3.
  41. Fragkioudaki S., Mavragani C.P., Moutsopoulos H.M. Predicting the risk for lymphoma development in Sjogren syndrome. Medicine (Baltimore). 2016; 95(25): e3766. https://dx.doi.org/10.1097/MD.0000000000003766.
  42. Peen E., Mellbye O.J., Haga H. IgA rheumatoid factor in primary Sjogren's syndrome. Scand J Rheumatol. 2009; 38(1): 46-49. https://dx.doi.org/10.1080/03009740802366043.
  43. Kitagawa T., Shibasaki K., Toya S. Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjogren's syndrome. Clin Rheumatol. 2012; 31(1): 105-12. https://dx.doi.org/10.1007/s10067-011-1789-z.
  44. Diaz-Lopez C., Geli C., Corominas H. et al. Are there clinical or serological differences between male and female patients with primary Sjogren's syndrome? J Rheumatol. 2004; 31(7): 1352-55.
  45. Диагностика и лечение прогрессирующего системного склероза (системной склеродермии). М34.0. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2019/02/22/ssd_klin_rekomendatsii.pdf (дата обращения - 11.02.2022).
  46. Avouac J., Clements P.J., Khanna D. et al. Articular involvement in systemic sclerosis. Rheumatology (Oxford). 2012; 51(8): 1347-56. https://dx.doi.org/10.1093/rheumatology/kes041.
  47. Федеральные клинические рекомендации по диагностике и лечению идиопатических воспалительных миопатий. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2018/07/18/clinrec_id_vosp_mio.pdf (дата обращения - 11.02.2022).
  48. Ide V., Bossuyt X., Blockmans D., De Langhe E. Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy. RMD Open. 2018; 4(2): e000661. https://dx.doi.org/10.1136/rmdopen-2018-000661.
  49. Koler R.A., Montemarano A. Dermatomyositis. Am Fam Physician. 2001; 64(9): 1565-72.
  50. Shmerling R.H., Delbanco T.L. The rheumatoid factor: An analysis of clinical utility. Am J Med. 1991; 91(5): 528-34. https://dx.doi.org/10.1016/0002-9343(91)90190-9.
  51. Cavagna L., Nuno L., Scire C.A. et al. Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: Review of the literature and report of the experience of AENEAS Collaborative Group. Clin Rev Allergy Immunol. 2017; 52(1): 71-80. https://dx.doi.org/10.1007/s12016-016-8528-9.
  52. Chen L., Somers A., Liu J. Antisynthetase syndrome and pleural effusion: A case report. Chest. 2020; 158(4): 1991-92. https://dx.doi.org/10.1016/j.chest.2020.08.1725.
  53. Шаяхметова Р.У., Ананьева Л.П. Смешанное заболевание соединительной ткани. Современная ревматология. 2019; 1: 11-18. [Shayakhmetova R.U., Ananyeva L.P. Mixed connective tissue disease. Sovremennaya revmatologiya = Modern Rheumatology Journal2019; 1: 11-18 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2019-1-11-18.
  54. Ungprasert P., Crowson C.S., Chowdhary V.R. et al. Epidemiology of mixed connective tissue disease, 1985-2014: A population-based study. Arthritis Care Res (Hoboken). 2016; 68(12): 1843-48. https://dx.doi.org/10.1002/acr.22872.
  55. John K.J., Sadiq M., George T. et al. Clinical and immunological profile of mixed connective tissue disease and a comparison of four diagnostic criteria.Int J Rheumatol. 2020; 2020: 9692030. https://dx.doi.org/10.1155/2020/9692030.
  56. Garcia-De La Torre I., Salazar-Paramo M., Salmon-De La Torre G. Mixed connective tissue disease. A clinico-serological study of 17 cases. Mol Biol Rep. 1996; 23(3-4): 153-57. https://dx.doi.org/10.1007/BF00351163.
  57. Mimura Y., Ihn H., Jinnin M. et al. Rheumatoid factor isotypes in mixed connective tissue disease. Clin Rheumatol. 2006; 25(4): 572-74. https://dx.doi.org/10.1007/s10067-005-0185-y.
  58. Colaris M.J.L., de Boer M., van der Hulst R.R., Cohen Tervaert J.W. Two hundreds cases of ASIA syndrome following silicone implants: a comparative study of 30 years and a review of current literature. Immunol Res. 2017; 65(1): 120-28. https://dx.doi.org/10.1007/s12026-016-8821-y.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies